Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
Hum Vaccin ImmunotherJun 9, 2026 (epub)
Alejandro Hoberman, Jibran Atwi, Peter Silas et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3b randomized controlled trial evaluated the safety and immunogenicity of co-administering the 4CMenB and MenACWY-CRM meningococcal vaccines in 940 healthy adolescents aged 16-18 years. The study found that the immune responses were non-inferior when the vaccines were administered together compared to when given separately, with confidence intervals for antibody responses exceeding 0.5.
Key findings
- The lower limit of 95% confidence intervals for antibody responses was >0.5 for co-administration versus separate administration.
- The safety profile of co-administered vaccines was comparable to that of 4CMenB alone.
- Most reactions to the vaccines were mild or moderate, with no unexpected side effects.
Why it matters
Understanding the safety and efficacy of co-administering meningococcal vaccines is crucial for optimizing vaccination strategies in adolescents, who are at higher risk for invasive meningococcal disease.